Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases

Oral anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) have shown significant benefit in the management of ALK-rearranged non-small cell lung cancer (NSCLC). However, almost all patients will experience disease progression after front-line ALK-TKIs such as crizotinib. Treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gafer, Huda, de Waard, Quincy, Compter, Annette, van den Heuvel, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663151/
https://www.ncbi.nlm.nih.gov/pubmed/31345828
http://dx.doi.org/10.1136/bcr-2018-227299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663151/
https://www.ncbi.nlm.nih.gov/pubmed/31345828
http://dx.doi.org/10.1136/bcr-2018-227299

Ejemplares similares